• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多因素预测分析非瓣膜性心房颤动患者抗凝治疗后国际标准化比值(INR)达标的影响因素。

A predictive study of multivariate factors affecting goal attainment of INR after anticoagulation in patients with nonvalvular atrial fibrillation.

机构信息

Department of Cardiovascular Medicine, Yibin First People's Hospital, Yibin, China.

Department of Cardiovascular Medicine, Xinqiao Hospital Affiliated to Army Military Medical University, Chonqing, China.

出版信息

Ann Palliat Med. 2021 Apr;10(4):4532-4538. doi: 10.21037/apm-21-549.

DOI:10.21037/apm-21-549
PMID:33966401
Abstract

BACKGROUND

Non-valvular atrial fibrillation (NVAF) is a common type of AF, and patients with NVAF have a higher risk of ischemic stroke than non-AF patients. This study aims to investigate the goal attainment of international normalized ratio (INR) in patients with NVAF after anticoagulation therapy, and to analyze the risk factors that affect the goal attainment of INR.

METHODS

NVAF patients who were admitted to our hospital from December 2019 to December 2020 and received anticoagulation therapy were selected as the research subjects. The INR goal attainment of patients was assessed, the risk factors affecting INR goal attainment were analyzed, and a ROC curve was drawn to evaluate the predictive value of risk factors for INR goal attainment in NVAF patients.

RESULTS

After anticoagulation treatment, the INR of 42 cases reached the target (INR value ≥0.2, the goal attainment group), and the INR of 74 cases did not reach the target (INR value <2.0, the non-goal attainment group). The age, mean platelet volume (MPV), platelet distribution width (PDW), and large platelet ratio (P-LCR) levels of patients in the goal attainment group were significantly lower than those in the non-goal attainment group, and the platelet count (PLT) level was higher than that of the non-goal attainment group (P<0.05). The results of multivariate logistic regression analysis showed that MPV, PDW, and P-LCR were independent risk factors that affected the failure in INR goal attainment in patients with NVAF after anticoagulation therapy. The ROC curve showed that the AUC values of MPV, PDW, and P-LCR were 0.711, 0.748, 0.867, respectively, and the combined AUC was 0.876, which was higher than that of the single detection.

CONCLUSIONS

MPV, PDW, and P-LCR are important factors that affect the goal attainment of INR after anticoagulant therapy in NVAF patients. For patients with risk factors, clinicians can formulate a reasonable individualized anticoagulant drug regimen based on the above-mentioned index levels.

摘要

背景

非瓣膜性心房颤动(NVAF)是一种常见的房颤类型,NVAF 患者发生缺血性脑卒中的风险高于非房颤患者。本研究旨在探讨 NVAF 患者抗凝治疗后国际标准化比值(INR)的达标情况,并分析影响 INR 达标情况的危险因素。

方法

选取 2019 年 12 月至 2020 年 12 月我院收治的 NVAF 患者,入选患者均接受抗凝治疗,评估患者 INR 达标情况,分析影响 INR 达标情况的危险因素,绘制 ROC 曲线评估危险因素对 NVAF 患者 INR 达标情况的预测价值。

结果

抗凝治疗后,42 例患者 INR 达标(INR 值≥0.2,达标组),74 例患者 INR 未达标(INR 值<2.0,未达标组)。达标组患者年龄、平均血小板体积(MPV)、血小板分布宽度(PDW)、大血小板比率(P-LCR)水平均显著低于未达标组,血小板计数(PLT)水平显著高于未达标组(P<0.05)。多因素 logistic 回归分析结果显示,MPV、PDW、P-LCR 是影响 NVAF 患者抗凝治疗后 INR 达标失败的独立危险因素。ROC 曲线显示,MPV、PDW、P-LCR 的 AUC 值分别为 0.711、0.748、0.867,联合 AUC 值为 0.876,均高于单项检测。

结论

MPV、PDW、P-LCR 是非瓣膜性心房颤动患者抗凝治疗后 INR 达标情况的重要影响因素。对于存在危险因素的患者,临床医生可根据上述指标水平制定合理的个体化抗凝药物治疗方案。

相似文献

1
A predictive study of multivariate factors affecting goal attainment of INR after anticoagulation in patients with nonvalvular atrial fibrillation.多因素预测分析非瓣膜性心房颤动患者抗凝治疗后国际标准化比值(INR)达标的影响因素。
Ann Palliat Med. 2021 Apr;10(4):4532-4538. doi: 10.21037/apm-21-549.
2
Relationship between platelet indices and international normalized ratio in patients with non-valvular atrial fibrillation.血小板指标与非瓣膜性心房颤动患者国际标准化比值的关系。
Platelets. 2014;25(5):311-6. doi: 10.3109/09537104.2013.821603. Epub 2013 Aug 23.
3
Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.抗血小板治疗与华法林联用的亚最佳抗凝治疗对非瓣膜性心房颤动患者临床结局的影响:一项全人群队列研究。
Heart Rhythm. 2016 Aug;13(8):1581-8. doi: 10.1016/j.hrthm.2016.03.049. Epub 2016 Mar 28.
4
Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation.非瓣膜性心房颤动患者缺血性卒中的病因
Cerebrovasc Dis. 2016;42(3-4):196-204. doi: 10.1159/000445723. Epub 2016 Apr 26.
5
International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation.华法林治疗的非瓣膜性心房颤动患者的国际标准化比值稳定性
Am J Cardiovasc Drugs. 2015 Jun;15(3):205-11. doi: 10.1007/s40256-015-0120-9.
6
International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation.非瓣膜性心房颤动初治华法林患者的国际标准化比值稳定情况
Curr Med Res Opin. 2014 Dec;30(12):2437-42. doi: 10.1185/03007995.2014.957822. Epub 2014 Sep 2.
7
Meta-Analysis Evaluating the Efficacy and Safety of Low-Intensity Warfarin for Patients >65 Years of Age With Non-Valvular Atrial Fibrillation.评价低强度华法林治疗非瓣膜性心房颤动 >65 岁患者的疗效和安全性的荟萃分析。
Am J Cardiol. 2021 Mar 1;142:74-82. doi: 10.1016/j.amjcard.2020.12.001. Epub 2020 Dec 8.
8
How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation?华法林治疗的非瓣膜性心房颤动患者的目标国际标准化比值(INR)水平维持得如何?
Yonsei Med J. 2009 Feb 28;50(1):83-8. doi: 10.3349/ymj.2009.50.1.83. Epub 2009 Feb 24.
9
Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.日本非瓣膜性心房颤动患者在接受华法林预防卒中时抗凝管理未达最佳状态。
J Stroke Cerebrovasc Dis. 2017 Oct;26(10):2102-2110. doi: 10.1016/j.jstrokecerebrovasdis.2017.04.030. Epub 2017 May 19.
10
Use of warfarin for nonvalvular atrial fibrillation in nursing home patients.华法林在疗养院患者非瓣膜性心房颤动治疗中的应用。
Arch Fam Med. 1995 Dec;4(12):1017-26. doi: 10.1001/archfami.4.12.1017.